Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | APP | P05067 | 5/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28376353 | 0.95 | KCNH2 (0.46) | KCNH2APPTAAR1PPARDPPARA | |
| SCHEMBL8748354 | 0.87 | CA12 (0.48) | KCNH2APPALDH1A1KMT2A | |
| SCHEMBL10840203 | 0.84 | KCNH2 (0.51) | KCNH2TAAR1PPARDPPARAMAOB | |
| SCHEMBL9864385 | 0.83 | TAAR1 (0.57) | TAAR1ALDH1A1CALM1MAOBSIGMAR1 | |
| SCHEMBL5535693 | 0.81 | MAOB (0.46) | APPTAAR1MAOBFFAR1 | |
| SCHEMBL22894194 | 0.81 | KMT2A (0.60) | KCNH2APPTAAR1PPARDPPARA | |
| SCHEMBL864988 | 0.81 | APP (0.65) | APPALDH1A1MAOBFFAR1KMT2A | |
| SCHEMBL19012412 | 0.81 | KMT2A (0.60) | KCNH2APPTAAR1PPARDPPARA | |
| SCHEMBL27496419 | 0.81 | TAAR1 (0.55) | TAAR1ALDH1A1CALM1MAOBSIGMAR1 | |
| SCHEMBL5784919 | 0.81 | MAOB (0.58) | KCNH2APPTAAR1PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2023-07-11 | — | — | US | claimed |
| CN-108409837-B | Glycopeptide compound with anti-drug resistance bacterial activity, preparation method and application thereof | 上海来益生物药物研究开发中心有限责任公司 | 2021-09-24 | — | — | CN | claimed |
| US-20210093691-A1 | Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2021-04-01 | — | — | US | claimed |
| EP-3763728-A1 | GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shanghai LaiYi Center For Biopharmaceutical R&D Co., Ltd. (CN) | 2021-01-13 | — | — | EP | claimed |
| WO-2019170046-A1 | GLYCOPEPTIDE COMPOUNDS HAVING ACTIVITY OF RESISTING DRUG-RESISTANT BACTERIA, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 上海来益生物药物研究开发中心有限责任公司 | 2019-09-12 | — | — | WO | claimed |
| EP-1880720-B1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO CO LTD (JP) | 2013-02-13 | — | — | EP | claimed |
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-11-26 | — | — | US | claimed |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAIICHI SANKYO COMPANY , LIMITED (JP) | 2009-05-07 | — | — | US | claimed |
| EP-1908466-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-04-09 | — | — | EP | claimed |
| EP-1880720-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Daiichi Sankyo Company, Limited (JP) | 2008-01-23 | — | — | EP | claimed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | claimed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | claimed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | claimed |
| EP-0549600-A1 | 5-TRIFLUOROACYLAMINO-2-ARYL OXAZOLES | PFIZER INC. (US) | 1993-07-07 | — | — | EP | claimed |
| WO-1992005163-A1 | 5-TRIFLUOROACYLAMINO-2-ARYL OXAZOLES | PFIZER INC. (US) | 1992-04-02 | — | — | WO | claimed |
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | SHANGHAI LAIYI CENTER FOR BIOPHARMACEUTICAL R&D CO., LTD. (CN) | 2023-07-11 | — | — | US | disclosed |
| CN-108409837-B | Glycopeptide compound with anti-drug resistance bacterial activity, preparation method and application thereof | 上海来益生物药物研究开发中心有限责任公司 | 2021-09-24 | — | — | CN | disclosed |
| WO-2000040576-A2 | THIOPYRAN COMPOUNDS AS INHIBITORS OF MMP | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
| WO-1998043649-A2 | AGE PRODUCTION INHIBITORY COMPOSITION COMPRISING A MAILLARD REACTION INHIBITOR AND VITAMIN B¿6? | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-10-08 | — | — | WO | disclosed |
| US-4578107-A | Herbicidal imidazolidine-2-one derivatives | OTSUKA KAGAKU KABUSHIKI KAISHA (JP) | 1986-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292024-A1 | SUBSTITUTED PROPANAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | PTMS, C1S, ACP3 | KCNH2 698/4885APP 133/4885TAAR1 2449/4885 |
| US-20210093691-A1 | Glycopeptide Compounds Having Activity Of Resisting Drug-Resistant Bacteria, And Preparation Method And Application Thereof | VIP, CUTA, MGAM | KCNH2 2659/4885APP 460/4885TAAR1 3759/4885 |
| US-20090118199-A1 | SUBSTITUTED ACRYLAMIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | ACR, NAT1, C1S | KCNH2 540/4885APP 329/4885TAAR1 260/4885 |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | KCNH2 4079/4885APP 45/4885TAAR1 948/4885 |
| US-11696937-B2 | Glycopeptide compounds having activity of resisting drug-resistant bacteria, and preparation method and application thereof | VIP, CUTA, MGAM | KCNH2 2659/4885APP 460/4885TAAR1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.